H. Lundbeck A/S

BATS-CHIXE:HLUNBC Stock Report

Market Cap: DKK 42.2b

H. Lundbeck Valuation

Is HLUNBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLUNBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

DKK 153.26
Fair Value
71.9% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: HLUNBC (DKK43.07) is trading below our estimate of fair value (DKK153.26)

Significantly Below Fair Value: HLUNBC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLUNBC?

Key metric: As HLUNBC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HLUNBC. This is calculated by dividing HLUNBC's market cap by their current earnings.
What is HLUNBC's PE Ratio?
PE Ratio11.6x
EarningsDKK 3.81b
Market CapDKK 42.16b

Price to Earnings Ratio vs Peers

How does HLUNBC's PE Ratio compare to its peers?

The above table shows the PE ratio for HLUNBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average13.1x
HIK Hikma Pharmaceuticals
12.3x13.17%UK£3.4b
HCM HUTCHMED (China)
5.4x-64.67%UK£1.9b
HLN Haleon
21.7x6.58%UK£33.0b
GSK GSK
13.1x8.69%UK£72.0b
HLUNBC H. Lundbeck
11.6x1.20%DKK 42.2b

Price-To-Earnings vs Peers: HLUNBC is good value based on its Price-To-Earnings Ratio (11.6x) compared to the peer average (13.1x).

Price to Earnings Ratio vs Industry

How does HLUNBC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies10PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HLUNBC is good value based on its Price-To-Earnings Ratio (11.6x) compared to the European Pharmaceuticals industry average (24.7x).

Price to Earnings Ratio vs Fair Ratio

What is HLUNBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLUNBC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HLUNBC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLUNBC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentDKK 43.07
DKK 48.32
+12.19%
18.87%DKK 72.00DKK 39.00n/a11
Nov ’26DKK 46.32
DKK 48.59
+4.90%
17.20%DKK 71.00DKK 41.00n/a11
Oct ’26DKK 46.60
DKK 48.18
+3.39%
17.61%DKK 71.00DKK 39.50n/a11
Sep ’26n/a
DKK 48.18
0%
17.61%DKK 71.00DKK 39.50n/a11
Aug ’26n/a
DKK 47.38
0%
18.38%DKK 72.00DKK 38.00n/a12
Jul ’26n/a
DKK 47.13
0%
18.07%DKK 72.00DKK 38.00n/a12
Jun ’26n/a
DKK 48.41
0%
17.31%DKK 72.00DKK 39.00n/a11
May ’26n/a
DKK 49.68
0%
15.68%DKK 70.00DKK 42.50n/a11
Apr ’26n/a
DKK 50.68
0%
14.86%DKK 70.00DKK 42.50n/a11
Mar ’26n/a
DKK 51.68
0%
16.90%DKK 71.00DKK 42.50n/a11
Feb ’26n/a
DKK 51.95
0%
16.37%DKK 71.00DKK 42.50n/a11
Jan ’26n/a
DKK 50.15
0%
14.83%DKK 69.00DKK 42.50n/a10
Dec ’25n/a
DKK 50.14
0%
14.04%DKK 69.00DKK 42.50DKK 43.0711
Nov ’25n/a
DKK 48.95
0%
9.18%DKK 57.00DKK 42.50DKK 46.3211
Oct ’25n/a
DKK 46.29
0%
12.51%DKK 57.00DKK 35.00DKK 46.6012
Sep ’25n/a
DKK 45.54
0%
11.96%DKK 57.00DKK 35.00n/a12
Aug ’25n/a
DKK 40.88
0%
12.46%DKK 55.00DKK 35.00n/a12
Jul ’25n/a
DKK 39.96
0%
10.94%DKK 51.00DKK 35.00n/a12
Jun ’25n/a
DKK 39.96
0%
10.94%DKK 51.00DKK 35.00n/a12
May ’25n/a
DKK 38.71
0%
12.30%DKK 50.00DKK 33.00n/a12
Apr ’25n/a
DKK 38.79
0%
12.18%DKK 50.00DKK 33.00n/a12
Mar ’25n/a
DKK 38.35
0%
12.50%DKK 50.00DKK 33.00n/a13
Feb ’25n/a
DKK 38.27
0%
11.05%DKK 48.00DKK 33.00n/a13
Jan ’25n/a
DKK 38.58
0%
10.44%DKK 48.00DKK 33.00n/a13
Dec ’24n/a
DKK 38.79
0%
10.78%DKK 48.00DKK 32.00n/a12
DKK 46.85
Fair Value
8.1% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/30 06:57
End of Day Share Price 2025/11/25 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

H. Lundbeck A/S is covered by 37 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily FieldBarclays
Rosie TurnerBarclays
Charles PitmanBarclays